This article is more than 5 years old. Information may no longer be current.
CRF announces late-breaking clinical trials for upcoming TCT meeting
Click Here to Manage Email Alerts
The Cardiovascular Research Foundation released the lineup of lineup of Late-breaking Clinical Trials and First Report Investigations scheduled for presentation at Transcatheter Cardiovascular Therapeutics Scientific Symposium. The meeting will be held in Denver from Oct. 29 to Nov. 2.
12 late-breaking clinical trials
CULPRIT-SHOCK: A randomized trial of multivessel PCI in cardiogenic shock
EXCEL QOL: Comparison of quality of life after PCI vs CABG in left main CAD
DKCRUSH-V: A randomized trial of double kissing crush vs. provisional stenting for treatment of distal left main bifurcation lesions
ABSORB IV: A comparison of 30-day outcomes from a randomized trial of a bioresorbable scaffold vs. metallic drug-eluting stent in patients with CAD
ABSORB III: A comparison of 3-year outcomes from a randomized trial of a bioresorbable scaffold vs. metallic DES in patients with CAD
PARTNER 2A and SAPIEN 3 Cost-effectiveness: Analysis of cost-effectiveness of transcatheter aortic valve replacement vs. surgical aortic valve replacement in intermediate-risk patients with aortic stenosis
SENIOR: A randomized trial of a bioabsorbable polymer-based DES vs. a bare-metal stent with short dual antiplatelet therapy in patients with CAD aged older than 75 years
DAPT STEMI: A randomized trial of 6-month vs 12-month DAPT after DES implantation in patients with STEMI
REDUCE: Comparison of 3-month vs 12-month DAPT after implantation of a bioabsorbable polymer-based metallic DES with a luminal CD34+ antibody coating in patients with ACS
PREVAIL: 5-year outcomes of left atrial appendage closure vs. medical therapy in patients with nonvalvular atrial fibrillation
ORBITA: A randomized, sham-controlled trial of PCI in patients with CAD
FAME 2: 3-year clinical and cost-effectiveness outcomes of PCI guided by fractional flow reserve in patients with CAD
In addition, 15 First Report Investigations will also be presented, including VAMPIRE 3, a randomized trial of distal filter protection during PCI of high-risk plaque; CrossBoss First, an analysis of antegrade dissection and re-entry compared with standard wire escalation for crossing chronic total occlusions; several trials on mitral valve replacement and repair; and much more.
Visit Healio/Intervention during and after the meeting for live updates.
For more information:
Cardiovascular Research Foundation. http://www.crf.org/tct/agenda/2017-late-breaking-trials-and-first-report-investigations.